Bulk Quote Inquiry

EG8-HM154-100μg / Inquiry

EG8-HM154-500μg / Inquiry

EG8-HM154-1mg / Inquiry

Human EGFRVIII Protein

Product Info

Recombinant Human EGFRVIII Protein is expressed from Expi293 with His tag and Avi tag at the N-terminal. It contains Leu25-Ser645.[Accession | P00533]

Molecular Weight

The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

Human EGFRVIII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human EGFRVIII is greater than 95% as determined by SEC-HPLC.


Immobilized Human EGFRVIII at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 10.8ng/ml determined by ELISA.

Batch to Batch Consistency

Immobilized Human EGFRVIII at 0.5μg/ml (100μl/Well). Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 13.0/13.5/13.8ng/ml determined by ELISA.


The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.




(1)Pedersen M W , Meltorn M , Damstrup L , et al. The type III epidermal growth factor receptor mutation Biological significance and potential target for anti-cancer therapy[J]. Annals of Oncology, 2001, 12(6):745-760.

Kactus Biosystems Co.Ltd
Online Message